Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is conducting a Phase 3 clinical study titled A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata. The study aims to assess the effectiveness and safety of baricitinib in treating severe alopecia areata in children, a condition characterized by significant hair loss.
The intervention being tested is baricitinib, an oral medication, administered in both high and low doses. The study also includes a placebo group for comparison. Baricitinib is intended to treat hair loss by targeting specific pathways involved in the condition.
The study design is interventional, with participants randomly allocated to different treatment groups. It follows a parallel model and employs double masking, meaning both participants and investigators are unaware of the treatment assignments. The primary purpose is to evaluate the treatment’s effectiveness.
The study began on February 3, 2023, and is currently recruiting participants. The primary completion date is not specified, but the last update was submitted on August 22, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study update could influence Eli Lilly’s stock performance by potentially enhancing investor confidence if baricitinib proves effective. Success in this trial could also impact the competitive landscape, as effective treatments for alopecia areata in children are limited.
The study is ongoing, and further details are available on the ClinicalTrials portal.